Matthew E. Falangas

Matthew E. Falangas serves as an Adjunct Research Professor of Internal Medicine and Infectious Diseases at the European University Cyprus and Adjunct Associate Professor of Medicine at Tufts University School of Medicine. He concurrently directs the Alpha Institute of Biomedical Sciences (AIBES) and the First Department of Internal Medicine at Hospital Health in Athens, Greece.

His academic qualifications include:

• DSc in Medical Sciences (1999), National and Kapodistrian University of Athens
• MSc in Epidemiology (1996), Harvard University School of Public Health
• MD with Excellence (1986), National and Kapodistrian University of Athens
• Certified Diplomate in Infectious Diseases (1996), American Board of Pathology
• Certified Diplomate in Pathology (1993), American Board of Pathology

Falangas specializes in antimicrobial resistance mechanisms in Gram-negative pathogens, antibiotic therapy optimization for multidrug-resistant infections, and evidence synthesis through systematic reviews. His work bridges clinical practice and laboratory research to address critical treatment gaps in infectious diseases.

Recent publications (2017-2024) demonstrate consistent focus on carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and novel agents like cefiderocol, emphasizing dosing strategies and comparative efficacy through rigorous meta-analyses and in vitro studies.

His scientific recognition includes:

• Top-20 most highly cited researcher in Internal Medicine globally (ScholarGPS, 2023)
• Most highly cited scholar in Microbiology in Greece (Research Gate, 2023)
• ESCMID Fellow award (2017)
• Maxwell Finland Young Investigator Award (1997)
• Edward Kass Award for Clinical Excellence (1994)

As Principal Investigator, he has secured industry funding (InfectoPharm, Tetraphase) for antibiotic trials and European Commission grants for resistance surveillance. He organizes the annual Top-10 on Infections seminar series and serves on editorial boards including Expert Review of Anti-Infective Therapy.